|
gptkbp:instanceOf
|
immunosuppressant
mTOR inhibitor
macrolide
|
|
gptkbp:alsoKnownAs
|
gptkb:rapamycin
|
|
gptkbp:approvedBy
|
gptkb:FDA
1999
|
|
gptkbp:ATCCode
|
L04AA10
|
|
gptkbp:bioavailability
|
14%
|
|
gptkbp:brand
|
gptkb:Rapamune
|
|
gptkbp:CASNumber
|
53123-88-9
|
|
gptkbp:category
|
immunosuppressants
antineoplastic agents
antifungal antibiotics
antiproliferative agents
|
|
gptkbp:contraindication
|
hypersensitivity to sirolimus
|
|
gptkbp:discoveredBy
|
gptkb:Surendra_Nath_Sehgal
|
|
gptkbp:discoveredIn
|
gptkb:Easter_Island
1972
|
|
gptkbp:drugInteraction
|
gptkb:milk
gptkb:cyclosporine
gptkb:rifampin
gptkb:ketoconazole
|
|
gptkbp:eliminationHalfLife
|
57-63 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C51H79NO13
|
|
gptkbp:hasPatent
|
US Patent 3,929,992
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sirolimus
|
|
gptkbp:KEGGID
|
D00751
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits mTOR
|
|
gptkbp:MeSH_ID
|
D020123
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
gptkb:Streptomyces_hygroscopicus
|
|
gptkbp:proteinBinding
|
92%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521
gptkb:DB00877
5284616
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
thrombocytopenia
hyperlipidemia
increased risk of infection
mouth ulcers
impaired wound healing
|
|
gptkbp:solubility
|
insoluble in water
|
|
gptkbp:UNII
|
W36ZG6FT64
|
|
gptkbp:usedFor
|
prevention of organ transplant rejection
treatment of lymphangioleiomyomatosis
treatment of tuberous sclerosis complex
|
|
gptkbp:bfsParent
|
gptkb:rapamycin
gptkb:Streptomyces_species
|
|
gptkbp:bfsLayer
|
6
|